<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336072">
  <stage>Registered</stage>
  <submitdate>8/10/2010</submitdate>
  <approvaldate>19/10/2010</approvaldate>
  <actrnumber>ACTRN12610000877088</actrnumber>
  <trial_identification>
    <studytitle>A randomised controlled trial of 'arthritis relief plus' for osteoarthritis of the knee</studytitle>
    <scientifictitle>A randomised placebo controlled trial of 4jointz for the symptoms of osteoarthritis of the knee</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>This study has not been listed with any other registry.</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis of the knee</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>4JOINTZ is a novel combination of synergistic blend of standardised botanical extracts.  It is topically applied and massaged directly into the joint(s).  Approximately 3 grams or less than half a teaspoon is massaged into the knee joint 3 times a day for a period of 12 weeks.</interventions>
    <comparator>Placebo product is made up of:
water - purified, aloe vera100% xanthan gum, cetyl alcohol, gycerl monosterate a/s, glycerol, methylparaben, dmdm hydantoin, dow corning 345, dow corning 200  350cts, olive oil, propyl paraben, propylene glycol, denatured ethanol, glycerol, caramel, choc brown ht,  eucalyptus fragrance synthetic.

It is applied in exactly the same way as the active product. Approximately 3 grams or less than half a teaspoon is massaged into the knee joint 3 times a day for a period of 12 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain assessment - Pain(VAS) visual analogue scales</outcome>
      <timepoint>Baseline, week 4, week 8, week 12, week 16.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>KOOS  (Knee injury and Osteoarthritis Outcome Score) knee survey.</outcome>
      <timepoint>Baseline, week 4, week 8, week 12, week 16.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Markers of inflammation 
- Urine marker of cartilage breakdown (CTX-2)</outcome>
      <timepoint>Baseline, week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>blood tests - interleukin 6 (iL6) and C reactive protein (CRP) inflammatory markers</outcome>
      <timepoint>Baseline, week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>American Collegeof Rheumatology (ACR) criteria for knee osteoarthritis*
 - Knee pain and  at least 3 of 6
    - Age &gt; 50 years 
    - Stiffness &lt; 30 minutes
    - Crepitus
    - Bony Tenderness
    - Bony enlargement
    - No palpable warmth

Pain visual analogue scale &gt;40mm
Age &gt;50</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Other forms of arthritis
- Xray showing Osteoarthritis Research Society                     International (OARSI) grade 3 joint space narrowing (JSN)
- Significant knee injury within last 6 months
- Inability to sign provide informed consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>9/09/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>140</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Arthritis Relief Plus Pty. Ltd.</primarysponsorname>
    <primarysponsoraddress>PO Box 7687
GCMC
Queensland 9726</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Arthritis Relief Plus Pty. Ltd.</fundingname>
      <fundingaddress>PO Box 7687
Gold Coast Mail Centre
Queensland 9726</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Menzies Research Institute</othercollaboratorname>
      <othercollaboratoraddress>17 Liverpool St
Hobart
Tasmania 7000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to determine the efficacy of arthritis relief plus for knee osteoarthritis pain.  THis is a mix of 20 natural therapies.  The design is randomised and double blind for 3 months followed by a one month wash out in 140 patients with significant knee pain due to arthritis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Tasmanian Health and Medical Human Research Ethics Comittee</ethicname>
      <ethicaddress>University of Tasmania Office for Research Services
Private Bag 01
Hobart Tasmania 7001</ethicaddress>
      <ethicapprovaldate>26/04/2010</ethicapprovaldate>
      <hrec>H10988</hrec>
      <ethicsubmitdate>4/12/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Graeme Jones</name>
      <address>Menzies Research Institute
17 Liverpool Street
Hobart 
Tasmania 7000</address>
      <phone>+61 3 6226 7705</phone>
      <fax>+61 3 6226 7764</fax>
      <email>graeme.jones@utas.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Graeme Jones</name>
      <address>Menzies Research Institute
17 Liverpool Street
Hobart 
Tasmania 7000</address>
      <phone>+61 3 6226 7705</phone>
      <fax>+61 3 6226 7764</fax>
      <email>graeme.jones@utas.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mel Clark</name>
      <address>Menzies Research Institute
17 Liverpool Street
Hobart 
Tasmania 7000</address>
      <phone>+61 3 6226 7779</phone>
      <fax>+61 3 62267764</fax>
      <email>melanie.clark@utas.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>